AstraZeneca seeks FDA approval for self-injectable nasal flu vaccine

AstraZeneca on Wednesday submitted an application to the FDA for approval of a self-administered nasal drug Flu vaccine Suitable for ages 2 to 49 years. vaccine, flu nebulizerI’ll be the first one home vaccine This will allow anyone aged 18 or over to regulate themselves and minors.

AstraZeneca said in a statement that if approved, FluMist would be injected into the nasal cavity similar to other nasal sprays, “providing individuals and families who want to protect their loved ones from the flu with a new, Convenient choice”. Press release.FluMist is approved as a flu vaccine, but currently can only be administered by a health care professional.

AstraZeneca said it hopes FluMist will increase the number of people vaccinated against the disease.According to the U.S. Centers for Disease Control and Prevention, 9 million people will get influenza during the 2021-2022 flu season website. Of those 9 million people, about 100,000 went to the hospital and 5,000 died from the flu.

Lisa Glasser, head of U.S. medical affairs, vaccines and immunotherapies, AstraZeneca Yahoo Finance The push for FDA approval on Tuesday stems from lessons learned during the Covid-19 pandemic.

“We put nasal swabs in people’s hands for COVID-19 testing, and people were able to handle and continue using them very easily,” Glasser said.

She said the company believes the FluMist vaccine will be easy to use and will come with specific instructions for injecting it. Nasal syringe. An official date for the vaccine’s release or details about the packaging and shipping process have not yet been announced.

AstraZeneca said it expects the drug to be available in the United States during the 2024-2025 flu season.

The company did not immediately respond to Gizmodo’s request for more information about how much the FluMist vaccine will cost or whether it will be covered by insurance.